Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2018 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring to Present at the 10th Annual Biotech Showcase

NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a late-stage clinical biopharmaceutical company focusing on the development and...
January 03, 2018 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent Member

NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative cancer...
December 14, 2017 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
December 07, 2017 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017

NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a late-stage clinical biopharmaceutical company focusing on the development of a...
December 04, 2017 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
November 30, 2017 09:58 ET | Source: BeyondSpring, Inc.

BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority

NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
November 09, 2017 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Reports Third Quarter 2017 Operational and Financial Results

NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a late-stage clinical biopharmaceutical company focusing on the development of a...
November 02, 2017 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring to Host Quarterly Operational Update Conference Call on November 9, 2017

NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...
October 26, 2017 08:30 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
October 23, 2017 08:30 ET | Source: BeyondSpring, Inc.

BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline

NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...